Funding

EU4Health

EU4Health is the EU’s ambitious response to COVID-19. The pandemic has a major impact on patients, medical and healthcare staff, and health systems in Europe. The new EU4Health programme will go beyond crisis response to address healthcare systems’ resilience.

EU4Health Objectives

The EU will invest €5.3 billion in current prices in actions within the work program of EU4Health. The program has 4 main objectives:

  1. Improve & foster health in the EU
  2. Protect people in the EU from serious cross-border threats to health
  3. Improve medicinal products, medical devices and crisis-relevant products
  4. Strengthen health systems

These objectives are implemented through annual work programmes. The 2021 work programme is divided in four strands: disease prevention, crisis preparedness, health systems, and digital, with a cross-cutting focus on cancer.

EU4Health Call Summary

A few of the calls have been summarized below:

EU4H-2021-PJ-07: Action grants to support implementation of best practices on the ground with direct impact on the effort to tackle mental health challenges during COVID-19

Total Budget: €750,000 for 1 or 2 projects

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 12 to 36 months

Consortium: Minimum 3 entities from 3 different eligible countries. Must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme.

The consortium must be composed by at least one NGO active in the field of mental health, preferably at EU level.

Scope: The aim of the action is to increase awareness, knowledge sharing and capacity building in the area of mental health.

It is expected that the implementation of best practices to address mental health challenges during the COVID-19 pandemic, for example targeting mental health in schools, will have a direct impact on the effort to reduce the burden in the Member States and will support health professionals and improve awareness.

The short-term impact would be achieved through an increased number of public health interventions being scaled up in all Member States and improvements in disease prevention and health promotion, and management policies, and awareness-building and training capacity for health professionals to strengthen the capacity and capabilities to address the mental health impact of health crisis. The long-term impact would be the identification of solutions to tackle specific mental health issues, both at personal and societal level. Networking between experts will also provide benefits for developing and improving public health policies.

EU / Academia-Research Institute / Mental health

 


EU4H-2021-PJ-10: Action grants to reduce liver and gastric cancers caused by infections

Total Budget: € 2M – up to 2 projects (One targeted to HBV and HCV and one targeted to Helicobacter pylori)

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 12 to 36 months

Consortium: Applications by either a sole applicant or by a consortium are acceptable (must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme).

Scope: The action aims to reduce the risk of liver cancers associated with infections caused by the Hepatitis B and Hepatitis C viruses and the risk of gastric cancers caused by Helicobacter pylori. Each of the three types of infectious agents will be addressed by specific approaches targeted to support vaccination in case of Hepatitis B virus and to drug treatment in case of Hepatitis C virus and Helicobacter pylori. Specific activities will be dedicated to the early detection of infections, the cornerstone strategy to reduce the risk of liver and gastric cancer caused by the three mentioned pathogens.

The expected results and impact are the reduction of incidence of Hepatitis B infections and chronic diseases and reduction of Hepatitis C and Helicobacter pylori related liver and gastric cancers, respectively.

EU / Academia-Research Institute / Infectious diseases – Virology – Immunology

 


EU4H-2021-PJ-13: Action grants to support the implementation of best practices in community-based services for the human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), tuberculosis, viral

Total Budget: € 5M – up to 5 projects

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 36 months

Consortium: Minimum 3 entities from 3 different eligible countries. Must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme

Scope: The action aims at strengthening and supporting community-based service organisations in the Member States and neighbouring countries in the implementation of people-centre effective and integrated interventions, as well as linkage to care amongst groups at high risk of contracting HIV/AIDS, tuberculosis, viral hepatitis and sexually transmitted infections. It will also directly contribute to national programmes and public health measures, thus, supporting the implementation of internationally agreed goals.

The expected results are:

  • Integrated community-based health services, including prevention, counselling, peer-support, harm-reduction, prison-in-reach and through-care services, as well as testing and linkage to care;
  • Capacity and network building in the areas of HIV/AIDS, hepatitis and tuberculosis, including training, promotion and use of relevant IT tools towards hard-to-reach populations;
  • Horizontal support tasks including organisation of meetings and exchange of information facilitating the participation of relevant civil society organisations and networks.

EU / Academia-Research Institute / Infectious diseases – Virology – Immunology

 


EU4H-2021-PJ-14: Action grants supporting training activities, implementation, and best practices (AMR)

Total Budget: € 7M – up to 5 projects

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 36 months

Consortium: Minimum 3 entities from 3 different eligible countries. Must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme

Scope: This action aims to support enhanced hospital and long-term care facilities infection prevention and control practices, as well as antimicrobial stewardship practices, and the development of best practices and implementation at all levels. It supports the commitment in the EU One Health Action Plan against AMR for the Commission to help to address patient safety in hospitals by supporting good practices in infection prevention and control and antimicrobial stewardship.

The support of capacity building is expected to enhance primary and secondary healthcare services.

An improved effectiveness of healthcare systems to prevent infection is likely to result in reductions in healthcare associated infections and improvements in patient safety in relation to AMR in the participating hospitals and long-term care facilities.

EU / Academia-Research Institute / Antibiotic Resistance Monitoring

 


EU4H-2021-PJ-15: Action grants for ‘Cancer Diagnostic and Treatment for All’ including ‘Genomic for Public Health’

Total Budget: € 3M for strand A and € 3M for strand B – up to 2 projects

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 36 months

Consortium: Applications by either sole applicants or by a consortium are acceptable. Must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme

Scope: The new ‘Cancer Diagnostic and Treatment for All’ initiative (Strand A), and the ‘Genomic for Public Health’ project (Strand B) will help Member States to improve access for individuals and cancer patients and survivors to prevention, diagnosis and treatment of cancer through personalised medicine, by upscaling available innovation in the field of innovative cancer diagnosis and treatment.

The ‘Cancer Diagnostic and Treatment for All’ and the ‘Genomic for Public Health’ actions will help Member States to develop guidelines and recommendations to better determine who and what to test, organise health services to implement genetic testing, and provide specific education and training for health workers to advance our understanding of cancer control. Ultimately, individuals and cancer patients will benefit on a large-scale of a high quality and viable way to prevent cancer, to diagnose and treat it.

EU / Academia-Research Institute / Oncology

 


EU4H-2021-PJ-16: Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project

Total Budget: € 3M – up to 2 projects

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 12 to 36 months

Consortium: Applications by either sole applicants or by a consortium are acceptable, but sole applicants or lead partners of a consortium need to provide proof of having prior relevant experience in the field concerned. Must be eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme

Scope: The aim of the action is to identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’ including by upscaling available innovation13 using advanced computing and the new big-data technologies and high-performance computing while reducing timeframes and development costs.

The launch of an EU platform based on improved ‘computational drug networks’ is expected to result in a better prediction of the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers, and to link Member States’ structures responsible for cancer treatment and care.

Starting with cancers with poor prognosis and rare cancers, and using high-performance computing, this work will help to improve the arsenal of anticancer drugs and overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.

The action is likely to increase available anticancer drugs and overcome limitations of current cancer therapies against old and new therapeutic targets in oncology, to the final benefit of patients with poor prognosis and rare cancers.

EU / Academia-Research Institute / Oncology

 


EU4H-2021-PJ-17: Action grants to organise and collect data to understand the safety, quality and efficacy of therapies applied in the field of assisted reproduction and based on haematopoietic stem cells

Total Budget: € 2M for strand A and € 2M for strand B – 1 project/strand

Deadline: 25 January 2022

Funding rate: 60% (co-financing required)

Project duration: 36 months

Consortium: Applications may be either by sole applicants or a consortium (no minimum requirement). Are eligible public or private entities established in EU Member State, Associated countries, or countries associated to the EU4Health Programme

Scope: This action will aim to collect and organise in registries data on the safety, quality and efficacy of therapies applied in the field of medically assisted reproduction (MAR, Strand A)and haematopoietic stem cell transplantation (Strand B).

The expected results are new or substantially upgraded digital registries with higher quality data entries from medical professionals across the Union and Member States authorities. This will provide good quality data collection on therapies in the field of MAR and based on haematopoietic stem cells and facilitate data sharing for open science and for Union legal requirements for oversight purposes, for monitoring safety and outcome as well as for the protection of donors and offspring.

Proposed solutions should ensure the findability, accessibility, interoperability, and reuse of digital assets (FAIR principles), use or interoperate with the main European and global data standards and other initiatives (i.e. European Health Data Space, EOSC Life).

Qualitative data will be available for professionals as well as authorities and other stakeholders in the sector and facilitate their respective tasks in the sector (such as clinical protocols, authorisations, market feedback, value-based reimbursement), while respecting the provisions on privacy protection (GDPR).

This will allow improving and promoting medical excellence, as well as increasing the efficiency of the healthcare systems and transparency for patients.

The action will have an impact on the digital transformation and uptake of digital solutions in the Union sector of MAR and hematopoietic stem cells, in order to facilitate the monitoring of activities and outcomes.

EU / Academia-Research Institute

 


Read more about the EU4Health programme 

Catalyze Figure Ovals Lightgray
Newsletter

A must-have if you’re interested in getting your business to the next level